NASDAQ · INDV
Healthcare · Drug Manufacturers - Specialty & Generic
$34.77
Up+$0.45 (+1.31%)
Updated Sep 10, 2026, 1:28 PM
SID Score
4.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INDV closed at $34.77 after 20 trading sessions, down 10.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $34.32 | $34.795 | $33.92 | $34.77 | 1.35M |
| Sep 8, 2026 | $34.35 | $34.8399 | $33.84 | $34.32 | 1.82M |
| Sep 4, 2026 | $34.74 | $35.31 | $34.55 | $34.94 | 1.02M |
| Sep 3, 2026 | $35.18 | $35.23 | $34.57 | $34.83 | 1.83M |
| Sep 2, 2026 | $34.74 | $35.28 | $34.68 | $35.05 | 2.97M |
| Sep 1, 2026 | $35.00 | $35.44 | $34.50 | $34.56 | 2.09M |
| Aug 31, 2026 | $34.87 | $35.30 | $34.33 | $34.93 | 1.96M |
| Aug 28, 2026 | $35.31 | $35.49 | $34.49 | $34.87 | 3.31M |
| Aug 27, 2026 | $35.61 | $35.95 | $35.11 | $35.30 | 1.22M |
| Aug 26, 2026 | $35.90 | $36.205 | $35.55 | $35.825 | 1.28M |
| Aug 25, 2026 | $36.23 | $36.75 | $35.61 | $35.97 | 1.71M |
| Aug 24, 2026 | $36.53 | $36.815 | $35.37 | $36.18 | 1.84M |
| Aug 21, 2026 | $37.68 | $38.52 | $36.70 | $36.87 | 2.5M |
| Aug 20, 2026 | $38.91 | $39.25 | $37.64 | $37.78 | 1.44M |
| Aug 19, 2026 | $39.90 | $40.00 | $38.725 | $39.04 | 2.48M |
| Aug 18, 2026 | $39.48 | $39.92 | $39.08 | $39.43 | 2.34M |
| Aug 17, 2026 | $38.95 | $39.59 | $38.6829 | $39.08 | 2.02M |
| Aug 14, 2026 | $38.00 | $39.14 | $37.82 | $39.01 | 988.4K |
| Aug 13, 2026 | $39.12 | $39.12 | $38.02 | $38.22 | 2.34M |
| Aug 12, 2026 | $38.50 | $39.15 | $37.855 | $38.73 | 2.57M |
The latest Smart Investors Daily articles mentioning INDV.
INDV research
Company profile and research snapshot.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Barclays | Overweight | — |
| Jun 18, 2026 | Barclays | Overweight | — |
| Jan 12, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 31, 2025 | Piper Sandler | Overweight | — |
| Oct 30, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Aug 31, 2026
Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Yahoo · Aug 27, 2026
Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.
Benzinga · Aug 17, 2026
Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INDV.
